| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 14/02/2024 | 22:12 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AYTU | AYTU BioPharma Inc |
| 13/02/2024 | 22:25 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:AYTU | AYTU BioPharma Inc |
| 02/01/2024 | 22:37 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AYTU | AYTU BioPharma Inc |
| 14/11/2023 | 22:05 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:AYTU | AYTU BioPharma Inc |
| 12/10/2023 | 20:50 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:AYTU | AYTU BioPharma Inc |
| 29/09/2023 | 22:15 | Edgar (US Regulatory) | Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | NASDAQ:AYTU | AYTU BioPharma Inc |
| 27/09/2023 | 13:28 | IH Market News | Wednesday’s Wall Street Highlights: Amazon, Costco, Sirius XM, Electronic Arts, Peloton, and more | NASDAQ:AYTU | AYTU BioPharma Inc |
| 23/06/2023 | 22:55 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 22/06/2023 | 22:06 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 20/06/2023 | 14:35 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 16/06/2023 | 22:49 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 12/06/2023 | 23:20 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 12/06/2023 | 23:12 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 09/06/2023 | 14:11 | Edgar (US Regulatory) | Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 05/06/2023 | 23:25 | Edgar (US Regulatory) | Securities Registration Statement (s-1/a) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 26/05/2023 | 19:53 | Edgar (US Regulatory) | Statement of Beneficial Ownership (sc 13d) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 11/05/2023 | 22:05 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 01/05/2023 | 23:21 | Edgar (US Regulatory) | Securities Registration Statement (s-1) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 15/02/2023 | 22:41 | Edgar (US Regulatory) | Notification That Quarterly Report Will Be Submitted Late (nt 10-q) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 16/11/2022 | 12:25 | TipRanks | H.C. Wainwright Keeps Their Buy Rating on Aytu BioScience (AYTU) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 14/11/2022 | 23:52 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 21/09/2022 | 14:00 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 15/08/2022 | 22:03 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 23/06/2022 | 12:02 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 08/06/2022 | 22:07 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 28/04/2022 | 12:17 | TipRanks | H.C. Wainwright Thinks Aytu BioScience’s Stock is Going to Recover | NASDAQ:AYTU | AYTU BioPharma Inc |
| 04/03/2022 | 12:02 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 22/02/2022 | 22:47 | Edgar (US Regulatory) | Amended Annual Report (10-k/a) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 11/02/2022 | 21:30 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:AYTU | AYTU BioPharma Inc |
| 14/12/2021 | 15:30 | PR Newswire (US) | Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome | NASDAQ:AYTU | AYTU BioPharma Inc |